Search Result

Results for "

positron+emission+tomography

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Linker (1) Amino Acid Derivatives (2) Amino acid Transporter (1) Amyloid-β (3) Angiotensin Receptor (1) Apoptosis (1) ASCT (1) Bcr-Abl (1) Biochemical Assay Reagents (9) c-Fms (1) Cannabinoid Receptor (2) Carbonic Anhydrase (1) Cholecystokinin Receptor (1) CXCR (2) Cytochrome P450 (1) Dopamine Receptor (3) Drug Derivative (2) Drug Intermediate (5) EGFR (1) Epigenetic Reader Domain (1) Exosomes (1) FAAH (1) FAP (4) Fluorescent Dye (1) GLUT (1) GlyT (1) GPR39 (1) HDAC (2) Histamine Receptor (1) HSP (1) iGluR (2) Integrin (1) Isotope-Labeled Compounds (3) Ligands for Target Protein for PROTAC (1) LPL Receptor (1) mAChR (1) MAGL (2) mGluR (1) Microtubule/Tubulin (1) Mitochondrial Metabolism (3) Monoamine Oxidase (1) Neurokinin Receptor (1) Neurotensin Receptor (1) Orexin Receptor (OX Receptor) (1) Oxidative Phosphorylation (1) P-glycoprotein (1) PARP (2) Phosphodiesterase (PDE) (5) Potassium Channel (1) PSMA (5) Radionuclide-Drug Conjugates (RDCs) (12) Reference Standards (1) Sigma Receptor (1) Tau Protein (6) TREM receptor (1) TSPO (2) Vasopressin Receptor (1) α-synuclein (1)
By Research Areas:	Cancer (37) Cardiovascular Disease (5) Inflammation/Immunology (5) Neurological Disease (38)

By Targets:

ADC Linker (1)

Amino Acid Derivatives (2)

Amino acid Transporter (1)

Amyloid-β (3)

Angiotensin Receptor (1)

Apoptosis (1)

ASCT (1)

Bcr-Abl (1)

Biochemical Assay Reagents (9)

c-Fms (1)

Cannabinoid Receptor (2)

Carbonic Anhydrase (1)

Cholecystokinin Receptor (1)

CXCR (2)

Cytochrome P450 (1)

Dopamine Receptor (3)

Drug Derivative (2)

Drug Intermediate (5)

EGFR (1)

Epigenetic Reader Domain (1)

Exosomes (1)

FAAH (1)

FAP (4)

Fluorescent Dye (1)

GLUT (1)

GlyT (1)

GPR39 (1)

HDAC (2)

Histamine Receptor (1)

HSP (1)

iGluR (2)

Integrin (1)

Isotope-Labeled Compounds (3)

Ligands for Target Protein for PROTAC (1)

LPL Receptor (1)

mAChR (1)

MAGL (2)

mGluR (1)

Microtubule/Tubulin (1)

Mitochondrial Metabolism (3)

Monoamine Oxidase (1)

Neurokinin Receptor (1)

Neurotensin Receptor (1)

Orexin Receptor (OX Receptor) (1)

Oxidative Phosphorylation (1)

P-glycoprotein (1)

PARP (2)

Phosphodiesterase (PDE) (5)

Potassium Channel (1)

PSMA (5)

Radionuclide-Drug Conjugates (RDCs) (12)

Reference Standards (1)

Sigma Receptor (1)

Tau Protein (6)

TREM receptor (1)

TSPO (2)

Vasopressin Receptor (1)

α-synuclein (1)

By Research Areas:

Cancer (37)

Cardiovascular Disease (5)

Inflammation/Immunology (5)

Neurological Disease (38)

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Isotope-Labeled Compounds

Art. -Nr.	Produktname	Target	Forschungsgebiete	Chemical Structure

HY-106244

DOTATATE 3 Publications Verification Oxodotreotide	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-125399

PSMA-11 1 Publications Verification HBED-CC-PSMA	PSMA Radionuclide-Drug Conjugates (RDCs)	Cancer
PSMA-11 is a small molecule ligand that targets prostate-specific membrane antigen (PSMA) and has the ability to inhibit PSMA activity. PSMA-11 can be used to synthesize ⁶⁸Ga-PSMA-11, a positron emission tomography (PET) tracer that can be used to image advanced prostate cancer .

HY-147173

FAPI-74	FAP	Cancer
FAPI-74 is a PET (positron emission tomography) tracer targeting the fibroblast activation protein (FAP). FAPI-74 can be used for FAP-positive tumor research .

HY-120947

AV-105	Drug Intermediate	Neurological Disease
AV-105 is a Florbetapir ( ¹⁸F)-radiolabeled slyrylpyridine tosylate precursor extracted from patent WO2010078370A1, example 1.5. AV-105 can synthesize ¹⁸F-radiolabeled compounds, which are used for positron emission tomography (PET) imaging of neurodegenerative diseases of the brain .

HY-101184

T807 2 Publications Verification AV-1451	Tau Protein	Neurological Disease
T807 a novel tau positron emission tomography (PET) tracer.

HY-106244A

DOTATATE acetate 3 Publications Verification Oxodotreotide acetate	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-141637

2-Deoxy-2-fluoro-D-glucose 2 Publications Verification 2-Fluoro-2-deoxy-D-glucose; 2-Deoxy-2-fluoro-D-glucopyranose; Fluorodeoxyglucose	Biochemical Assay Reagents	Cancer
2-Deoxy-2-fluoro-D-glucose (2-Fluoro-2-deoxy-D-glucose) is a glucose analog that can be absorbed by cells. 2-Deoxy-2-fluoro-D-glucose is capable of being labelled with ¹⁸F for positron emission tomography (PET) imaging. ¹⁸F-2-Deoxy-2-fluoro-D-glucose can be used to detect breast cancer and gastric cancer .

HY-160116

α-Synuclein aggregate binder 1	Radionuclide-Drug Conjugates (RDCs) Fluorescent Dye α-synuclein	Neurological Disease
α-Synuclein aggregate binder 1 (Compound C05-05) is a specific binder for α-synuclein aggregates and can inhibit α-synuclein aggregation. α-Synuclein aggregate binder 1 can be used as a fluorescent probe (excitation wavelength 900 nm, detection wavelength 500-550 nm) for optical imaging, and can also inhibit α-synuclein fibril formation by blocking the aggregation process. α-Synuclein aggregate binder 1 can be used for positron emission tomography (PET) imaging after being labeled with ¹⁸F. α-Synuclein aggregate binder 1 can be used for visual diagnosis of brain lesions and mechanism research of neurodegenerative diseases such as Parkinson's disease and Lewy body dementia .

HY-153549

Pentixafor 2 Publications Verification	Radionuclide-Drug Conjugates (RDCs) CXCR	Others
Pentixafor is a peptide that targets CXCR4. Pentixafor is capable of being labelled with ⁶⁸Gallium ( ⁶⁸Ga) for positron emission tomography (PET) imaging . Pentixafor can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-153248

PBR28	Biochemical Assay Reagents	Neurological Disease Inflammation/Immunology
PBR28 is a translocator protein (TSPO) binding positron emission tomography (PET) radiotracer with blood-brain barrier permeability . PBR28 binds to TSPO, a marker of microglial activation and neuroinflammation, and is used for neuroinflammation imaging in brain diseases and HIV-infected individuals .

HY-75706

N-Descyclopropanecarbaldehyde Olaparib	PARP Ligands for Target Protein for PROTAC	Cancer
N-Descyclopropanecarbaldehyde Olaparib is an analogue of Olaparib (HY-10162) containing DOTA moiety. N-Descyclopropanecarbaldehyde Olaparib is a PARP inhibitor used for synthesizing novel dual EGFR and PARP PROTAC, DP-C-4 (HY-141481) . N-Descyclopropanecarbaldehyde Olaparib can be radiolabeled with F-18 or fluorophore for positron emission tomography (PET) or optical imaging in several types of tumor .

HY-117756

Piflufolastat DCFPYL	PSMA	Cancer
Piflufolastat (DCFPYL) can be used for the preparation of piflufolastat F 18 (DCFPyL F-18). Piflufolastat F-18 (DCFPyL F-18) is an ¹⁸F-labeled imaging agent. Piflufolastat F-18 can be used for positron emission tomography (PET) targeting prostate-specific membrane antigen (PSMA). Piflufolastat can be used for imaging of prostate cancer .

HY-101185

T808	Tau Protein	Neurological Disease
T808 is a selective tau protein-targeting ligand. T808 can be used to synthesize [ ¹⁸F]-T808, a highly selective tau protein positron emission tomography (PET) tracer. T808 can also be used to synthesize [ ³H]-T808, a marker for in vitro experiments. T808 can be used for the research of alzheimer’s disease .

HY-152148

JZP-MA-11	MAGL	Neurological Disease
JZP-MA-11 is a brain-penetrant positron emission tomography (PET) ligand targeting the brain endocannabinoid α/β-hydrolase domain 6 (ABHD6) enzyme. JZP-MA-11 selectively inhibits ABHD6 with an IC₅₀ value of 126 nM. [18F]JZP-MA-11 has the potential for preclinical evaluation targeting the brain ABHD6 in mice and nonhuman primate (NHP) .

HY-149766

PB94	HDAC	Neurological Disease
PB94 is a selective HDAC11 inhibitor (IC₅₀=108 nM). PB94 can be radiolabeled as [11C]-PB94 for use in positron emission tomography (PET), as well as brain uptake and metabolic properties in administered live animals. PB94 improves neuropathic pain in mice and could be used to study neurological indications .

HY-122607

DPA-714	Mitochondrial Metabolism TSPO	Inflammation/Immunology Cancer
DPA-714 is a high affinity translocator protein (TSPO) ligand (K_i=7 nM), which is designed with a fluorine atom in its structure, allowing labelling with fluorine -18 and in vivo imaging using positron emission tomography. ^18FDPA-714 successfully evaluates for the specific imaging of inflammation in various models of neuroinflammation and in a brain tumor model .

HY-100133A

DOTA-ADIBO TFA	Integrin	Cancer
DOTA-ADIBO TFA is a DOTA-derived bifunctional chelator (BFC) that allows drug conjugation via an uncatalyzed, copper-free cycloaddition reaction. DOTA-ADIBO TFA enables the construction of fusion chelator systems that can be further used to synthesize radiotracers after Cu[64] modification. Positron emission tomography imaging of tumors expressing integrin αvβ6 .

HY-119190

PF-06445974	Phosphodiesterase (PDE)	Neurological Disease
PF-06445974, a promising positron emission tomography (PET) lead, has exquisite potency at PDE4B with an IC₅₀ <1 nM. The IC₅₀ values are 36, 4.7 and 17 nM for PDE4D, PDE4A and PDE4C, respectively. PF-06445974 has good selectivity over PDE4D, excellent brain permeability, and a high level of specific binding in the "cold tracer" study .

HY-137557

Florzolotau APN1607; PM-PBB3	Tau Protein	Neurological Disease
Florzolotau (APN1607) is a positron emission tomography (PET) ligand that can be used for the detection of Alzheimer's disease (AD) and other tau proteinopathies. Its binding sites are located in the β-sheet of paired helical filaments (PHFs) and straight filaments (SFs) of tau protein, as well as in the C-shaped cavity of SFs. In addition, APN-1607 binds to intraneuronal inclusions in Alzheimer's disease (AD), primary age-related tauopathy (PART) and posterior cortical atrophy (PCA). Florzolotau shows promise for PET imaging studies of neurological disorders, particularly tau proteinopathies .

HY-100275

MK-3328	Amyloid-β	Neurological Disease
MK-3328 is a β-Amyloid ligand, which exhibits high binding potency with an IC₅₀ of 10.5 nM. MK-3328 is capable of being labelled with ¹⁸F for positron emission tomography (PET) imaging .

HY-139048

Fluoroethylnormemantine	iGluR	Neurological Disease
Fluoroethylnormemantine, a derivative of Memantine, is an antagonist of the N-methyl-D-aspartate (NMDA) receptor. [ ¹⁸F]-Fluoroethylnormemantine can be used as a positron emission tomography (PET) tracer. Fluoroethylnormemantine exhibits anti-amnesic, neuroprotective, antidepressant-like and fear-attenuating effects .

HY-135497

Fallypride	Dopamine Receptor	Neurological Disease
Fallypride is a potent antagonist of dopamine D2/D3 receptor. Fallypride, in the form of fallypride ( ¹⁸F), can be used as a positron emission tomography (PET) radiotracer .

HY-128890B

DOTA-NHS-ester TFA 1 Publications Verification	ADC Linker Biochemical Assay Reagents	Cancer
DOTA-NHS-ester (TFA) is used as a linker for affibody molecules, and it can be employed in small animal positron emission tomography (PET), single photon emission computed tomography (SPECT), and CT scanning. DOTA-NHS-ester can be used to label radiotracers or imaging probes for tumor detection .

HY-159108

AZ683	c-Fms	Cardiovascular Disease
AZ683 is a potent and selective 3-amido-4-anilinoquinoline CSF1R inhibitor. AZ683 has high affinity for CSF1R (K_i=8 nM; IC₅₀=6 nM). AZ683 has good oral bioavailability. [ ¹¹C]AZ683 can be used as a positron emission tomography (PET) radiotracer for colony stimulating factor 1 receptor (CSF1R) .

HY-160607

MMA-NODAGA	Radionuclide-Drug Conjugates (RDCs) Exosomes	Others
MMA-NODAGA is a chelator for site-specific labeling of targeting proteins containing unpaired cysteine. MMA-NODAGA can be used to conjugate with exosome and ⁶⁴Cu in image with positron emission tomography (PET) ^<[2].

HY-173291

Tau ligand-1	Tau Protein	Neurological Disease
Tau ligand-1 (Compound 75) is a ligand for aggregated tau protein that can penetrate the blood-brain barrier . In tissues from patients with Alzheimer's disease, progressive supranuclear palsy, corticobasal degeneration, and Pick's disease, Tau ligand-1 exhibits high affinity for aggregated tau protein, with equilibrium dissociation constant (K_D) values ranging from 1 to 3.8 nM . Tau ligand-1 can serve as a potential positron emission tomography (PET) tracer and holds promise for application in positron emission tomography imaging studies of tau-related diseases in the central nervous system .

HY-P5413

[Lys3]-Bombesin	Cholecystokinin Receptor	Others
[Lys3]-Bombesin is a biological active peptide. (PET (Positron Emission Tomography) imaging of [Lys3]-bombesin is able to detect gastrin-releasing peptide receptor (GRPR) positive prostate cancer. An immunoconjugate of [Lys3]-bombesin and corresponding monoclonal antibody can specifically induce (CD64)-dependent monocyte and neutrophil-mediated lysis of small cell carcinoma.)

HY-76573

ML-10	Apoptosis	Cardiovascular Disease Cancer
ML-10 is a small molecule apoptosis probe. Due to the presence of fluorine atoms, ML-10 can be radiolabeled with ¹⁸F isotopes and can be used for apoptosis positron emission tomography imaging studies. ML-10 is selectively taken up and accumulated in apoptotic cells, while being excluded from live or necrotic cells. In addition, the uptake of ML-10 is associated with apoptotic features such as caspase activation, Annexin-V binding, and disruption of mitochondrial membrane potential .

HY-129059

Odapipam 2 Publications Verification NNC 756	Dopamine Receptor	Neurological Disease
Odapipam (NNC 756) is a selective, high affinity and benzazepine dopamine D₁ receptor antagonist with a K_d of 0.18 nM. Odapipam is also a superior positron emission tomography (PET) radiotracer .

HY-171806

BMT-136088	LPL Receptor	Cancer
BMT-136088 is a LPAR1 antagonist . ¹¹C-BMT-136088 can be used as a positron emission tomography (PET) radioligand to quantify specific binding to LPA1 in lung.

HY-W100209

5Me3F4AP	Potassium Channel	Neurological Disease
5Me3F4AP is a potent blocker of potassium channel, with the IC₅₀ of 220 μM to 693 μM when the pH is increased from 6.4 to 9.1. 5Me3F4AP has the potential to cross the blood-brain barrier and potential application in positron emission tomography (PET) .

HY-141464

Fmoc-L-Asn(beta-D-GlcNAc(Ac)3)-OH Fmoc-Asn(Ac3AcNH-beta-Glc)-OH	Amino Acid Derivatives	Cancer
Fmoc-L-Asn(beta-D-GlcNAc(Ac)3)-OH (Fmoc-Asn(Ac3AcNH-beta-Glc)-OH) can be used in the synthesis of silicon-fluoride acceptor (SiFA) derivatized octreotate derivatives. SiFA-octreotate analogues, as tumor imaging agents, are useful tool for the research of positron emission tomography (PET) .

HY-175730

CB2R ligand-1	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology Cancer
CB2R ligand-1 (Compound L14) is a selective Cannabinoid type 2 receptor (CB2R) ligand with a with K_i of 0.16  nM for CB2R over CB1R. CB2R ligand-1 as be used as a tracer for positron emission tomography (PET) imaging of neurodegenerative diseases, inflammation and cancer .

HY-178871

OX2-2303	Orexin Receptor (OX Receptor)	Neurological Disease
OX2-2303 is a potent, selective orexin-2 receptor (OX₂R) antagonist. OX2-2303 exhibits excellent binding affinity towards OX₂R (K_i = 0.1 nM), and shows >890-fold selectivity over OX₁R. OX2-2303 can be used as a positron emission tomography (PET) radioligand for central nervous system (CNS) research .

HY-101184R

T807 (Standard) AV-1451 (Standard)	Reference Standards Tau Protein	Neurological Disease
T807 (Standard) is the analytical standard of T807. This product is intended for research and analytical applications. T807 a novel tau positron emission tomography (PET) tracer.

HY-206852

PF-06445974 precursor	Drug Intermediate Phosphodiesterase (PDE)	Neurological Disease
PF-06445974 precursor (Compound 28) is a nitro precursor and synthetic intermediate. PF-06445974 precursor can be used for the synthesis of PF-06445974 (HY-119190). PF-06445974 is a positron emission tomography (PET) compound that acts potently on PDE4B .

HY-175330

FAP-IN-6	FAP	Cancer
FAP-IN-6 (Compound 21) is a selectivity FAP inhibitor with an IC₅₀ of 13 pM. FAP-IN-6 has a high metabolic stability. FAP-IN-6 labeled with 18F can be used as a positron emission tomography (PET) tracer. FAP-IN-6 can be used for microenvironment of cancers research .

HY-P10220

NOTA-COG1410	Radionuclide-Drug Conjugates (RDCs) TREM receptor	Cancer
NOTA-COG1410 forms triggering receptor expressed on myeloid cells 2 (TREM2) targeting ligand. NOTA-COG1410 is capable of being labelled with ⁶⁸Gallium ( ⁶⁸Ga) for discovery and diagnosis of digestive system tumors through positron emission tomography/computed tomography (PET/CT). NOTA-COG1410 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-164475

PARP1-IN-29	PARP	Cancer
PARP1-IN-29 is an orally active PARP-1 inhibitor with an IC₅₀ value of 6.3 nM. PARP1-IN-29, after being labeled with [18F], can be used for positron emission tomography (PET) imaging, specifically targeting PARP-1 in tumors. PARP1-IN-29 is applicable in the fields of oncology and imaging research, particularly for detecting PARP-1 activity in cancer .

HY-176834

3-Deoxy-3-fluoro-D-fructose	GLUT	Cancer
3-Deoxy-3-fluoro-D-fructose (Compound 12) is a derivative of 2,5-Anhydro-D-mannitol. 3-Deoxy-3-fluoro-D-fructose is a selective probe of Hexose transporter 5 (GLUT5). 3-Deoxy-3-fluoro-D-fructose inhibits the transport of D-fructose labeled with 14C by GLUT5 with IC₅₀s of 1.16 and 2.37 µM in EMT-6 and MCF-7 cells. 3-Deoxy-3-fluoro-D-fructose can be used for positron emission tomography (PET) imaging of cancers .

HY-179227

HDAC6 ligand-7	HDAC	Neurological Disease
HDAC6 ligand-7 (Compound 16a) is a positron emission tomography (PET) tracer for the deacetylase 6 (HDAC6) enzyme with a K_d value of 1.66 nM. HDAC6 ligand-7 exhibits excellent HDAC6 inhibitory activity, with IC₅₀ values of 2.7 and 3.7 nM for hHDAC6 and mHDAC6, respectively, and has high selectivity for HDAC1/4/7/8. HDAC6 ligand-7 after being radioactively labeled with fluorine-18, [¹⁸F]HDAC6 ligand-7 shows varying degrees of radioactive uptake in PET, which can reflect the specific binding to HDAC6. HDAC6 ligand-7 can be used for the study of HDAC6 imaging .

HY-159001

ZCDD083	Biochemical Assay Reagents	Others
ZCDD083 can be used as a positron emission tomography (PET) tracer for atherosclerotic plaques imagination, when labeled with ¹⁸F isotope .

HY-173319

FAP-IN-5	FAP	Cancer
FAP-IN-5 (Compound 4a) is an FAP inhibitor with an IC₅₀ of 1.7 nM. FAP-IN-5 can be used in the research of tumor positron emission tomography (PET) imaging .

HY-111514

4-(6-Bromo-2-benzothiazolyl)benzenamine	Oxidative Phosphorylation Amyloid-β	Neurological Disease
4-(6-Bromo-2-benzothiazolyl)benzenamine is a β-amyloid PET (positron emission tomography) tracer that can be used in the diagnosis of neurological diseases, such as Alzheimer's and Down's syndrome.

HY-158317

SFB-AMD3465	CXCR Biochemical Assay Reagents	Others
SFB-AMD3465 is an AMD3465 (HY-15971A) derivative. SFB-AMD3465 is utilized as positron emission tomography (PET) tracer for CXCR4, when labeled with radioactive Fluorine .

HY-103326

NIDA-41020	Cannabinoid Receptor	Neurological Disease
NIDA-41020 is a potent and selective cannabinoid receptor 1(CB1) antagonist with a K_i of 4.1 nM. NIDA-41020 was designed as a potential radioligand for use in positron emission tomography (PET) .

HY-D2334

AlF-NOTA-c-d-VAP	Radionuclide-Drug Conjugates (RDCs) HSP	Cancer
AlF-NOTA-c-d-VAP is a peptide positron emission tomography (PET) probe that used for targeted tumor imaging of GRP78. AlF-NOTA-c-d-VAP demonstrates high stability in vitro and in vivo .

HY-117502

SL-25.1188	Monoamine Oxidase	Others
SL-25.1188 is a potent monoamine oxidase B (MAO-B) inhibitor with K_i values of 2.9 and 8.5 nM for human MAO-B and rat MAO-B, respectively. SL-25.1188 can be used for positron emission tomography .

HY-139048A

Fluoroethylnormemantine hydrochloride	iGluR	Neurological Disease
Fluoroethylnormemantine hydrochloride, a derivative of Memantine, is an antagonist of the N-methyl-D-aspartate (NMDA) receptor. [ ¹⁸F]-Fluoroethylnormemantine hydrochloride can be used as a positron emission tomography (PET) tracer. Fluoroethylnormemantine hydrochloride exhibits anti-amnesic, neuroprotective, antidepressant-like and fear-attenuating effects .

HY-146102

M1 ligand 1	mAChR	Others
M1 ligand 1 (compound 3b-b) is a muscarinic acetylcholine receptor M1 ligand. M1 ligand 1 is a N-desmethyl congener of arecoline derivative. M1 ligand 1 can be used as PET (positron emission tomography) radiotracer .

Art. -Nr.	Produktname	Type

HY-141637

2-Deoxy-2-fluoro-D-glucose 2 Publications Verification 2-Fluoro-2-deoxy-D-glucose; 2-Deoxy-2-fluoro-D-glucopyranose; Fluorodeoxyglucose	Biochemical Assay Reagents
2-Deoxy-2-fluoro-D-glucose (2-Fluoro-2-deoxy-D-glucose) is a glucose analog that can be absorbed by cells. 2-Deoxy-2-fluoro-D-glucose is capable of being labelled with ¹⁸F for positron emission tomography (PET) imaging. ¹⁸F-2-Deoxy-2-fluoro-D-glucose can be used to detect breast cancer and gastric cancer .

HY-100133A

DOTA-ADIBO TFA	Biochemical Assay Reagents
DOTA-ADIBO TFA is a DOTA-derived bifunctional chelator (BFC) that allows drug conjugation via an uncatalyzed, copper-free cycloaddition reaction. DOTA-ADIBO TFA enables the construction of fusion chelator systems that can be further used to synthesize radiotracers after Cu[64] modification. Positron emission tomography imaging of tumors expressing integrin αvβ6 .

Art. -Nr.	Produktname	Target	Research Area

HY-106244

DOTATATE 3 Publications Verification Oxodotreotide	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-106244A

DOTATATE acetate 3 Publications Verification Oxodotreotide acetate	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-153549

Pentixafor 2 Publications Verification	Radionuclide-Drug Conjugates (RDCs) CXCR	Others
Pentixafor is a peptide that targets CXCR4. Pentixafor is capable of being labelled with ⁶⁸Gallium ( ⁶⁸Ga) for positron emission tomography (PET) imaging . Pentixafor can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10734

NODAGA-RGD	Peptides
NODAGA-RGD is a peptide that can be radiolabeled and used as a radiotracer for positron emission tomography (PET) diagnosis .

HY-P5413

[Lys3]-Bombesin	Cholecystokinin Receptor	Others
[Lys3]-Bombesin is a biological active peptide. (PET (Positron Emission Tomography) imaging of [Lys3]-bombesin is able to detect gastrin-releasing peptide receptor (GRPR) positive prostate cancer. An immunoconjugate of [Lys3]-bombesin and corresponding monoclonal antibody can specifically induce (CD64)-dependent monocyte and neutrophil-mediated lysis of small cell carcinoma.)

HY-P10220

NOTA-COG1410	Radionuclide-Drug Conjugates (RDCs) TREM receptor	Cancer
NOTA-COG1410 forms triggering receptor expressed on myeloid cells 2 (TREM2) targeting ligand. NOTA-COG1410 is capable of being labelled with ⁶⁸Gallium ( ⁶⁸Ga) for discovery and diagnosis of digestive system tumors through positron emission tomography/computed tomography (PET/CT). NOTA-COG1410 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P10744

BQ7859	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
BQ7859 is a probe targeting PSMA that contains a NOTA chelator and demonstrates excellent imaging performance. BQ7859 can be labeled with various radionuclides, such as 68Ga, 18F, 55Co, and 111In. In a mouse prostate cancer xenograft model, BQ7859 (labeled with 111In) efficiently accumulates in tumor regions in a PSMA-dependent manner and provides high-contrast tumor imaging. BQ7859 shows potential for research in prostate cancer imaging, particularly in positron emission tomography (PET) and single-photon emission computed tomography (SPECT) . BQ7859 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P11845

DOTA-NT-20.3-IPBA	Radionuclide-Drug Conjugates (RDCs) Neurotensin Receptor	Cancer
DOTA-NT-20.3-IPBA is a Neurotensin receptor 1 (NTR1)-targeting albumin binder with specific high-affinity binding to NTR1. DOTA-NT-20.3-IPBA is formed by the conjugation of DOTA-NT-20.3 and IPBA. DOTA-NT-20.3-IPBA can be used for positron emission tomography (PET) imaging following labeling with [ ⁶⁸Ga]Ga .

Art. -Nr.	Produktname	Chemical Structure

HY-169071S

ATX-1905
ATX-1905 is a positron emission tomography (PET) tracer that demonstrates good autotaxin (ATX) binding specificity and achieves semiquantification of lung ATX expression levels, which are elevated in fibrotic lungs. ATX-1905 exhibits elevated uptake in Bleomycin (HY-108345)-induced pulmonary fibrosis (BPF) lungs. ATX-1905 is promising for research of idiopathic pulmonary fibrosis (IPF) .

HY-141637S

2-Deoxy-2-fluoro-D-glucose-13C

2-Deoxy-2-fluoro-D-glucose- ¹³C is the ¹³C labeled 2-Deoxy-2-fluoro-D-glucose (HY-141637). 2-Deoxy-2-fluoro-D-glucose (2-Fluoro-2-deoxy-D-glucose) is a glucose analog that can be absorbed by cells. 2-Deoxy-2-fluoro-D-glucose is capable of being labelled with ¹⁸F for positron emission tomography (PET) imaging. ¹⁸F-2-Deoxy-2-fluoro-D-glucose can be used to detect breast cancer and gastric cancer .

HY-141637S1

2-Deoxy-2-fluoro-D-glucose-13C6,d7

2-Deoxy-2-fluoro-D-glucose- ¹³C₆,d₇ is the ¹³C-labeled and deuterium labeled 2-Deoxy-2-fluoro-D-glucose (HY-141637). 2-Deoxy-2-fluoro-D-glucose (2-Fluoro-2-deoxy-D-glucose) is a glucose analog that can be absorbed by cells. 2-Deoxy-2-fluoro-D-glucose is capable of being labelled with ¹⁸F for positron emission tomography (PET) imaging. ¹⁸F-2-Deoxy-2-fluoro-D-glucose can be used to detect breast cancer and gastric cancer .

HY-122607S

DPA-714-d10

DPA-714-d₁₀ is the deuterium labeled DPA-714 (HY-122607). DPA-714 is a high affinity translocator protein (TSPO) ligand (K_i=7 nM), which is designed with a fluorine atom in its structure, allowing labelling with fluorine -18 and in vivo imaging using positron emission tomography. ¹⁸FDPA-714 successfully evaluates for the specific imaging of inflammation in various models of neuroinflammation and in a brain tumor model.

Online-Anfrage

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Anrede			Country or Region *
Name des Antragstellers *			Name der Organisation *
Department *
E-Mail-Addresse *			Produktname *
Art. -Nr.			Requested quantity *
Telefonnummer *
Bemerkungen

Online-Anfrage

Inquiry Information

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent: